Vascular Biogenics

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Notable Labs Ltd. is a clinical-stage platform therapeutics company that develops predictive medicines for patients with cancer. Through its proprietary Predictive Medicines Platform, the firm predicts whether or not that patient is likely to respond to that specific therapeutic. The company's Predictive Medicines Platform is designed to identify and select patients expected to be clinically responsive prior to their treatment to improve patient outcomes and fast-track clinical development. The firm's product candidate, Volasertib, is a Polo-like Kinase 1 inhibitor. Notable Labs was founded on January 31, 2000 and is headquartered in Foster City, CA.

Agreement extends current cash runway to Q1 2023 Agreement extends current cash runway to Q1 2023

VBL Therapeutics Enters Into Ordinary Share Purchase Agreement of up to $20 Million With Aspire Capital Fund, LLC

TEL AVIV, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the expansion of its ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111), for the treatment of platinum-resistant ovarian cancer into Europe, where the first patient has now been enrolled. The study continues to actively recruit patients in the U.S. and Israel, with over 200 patients enrolled to date.

VBL Therapeutics Announces First Patient in Europe in the OVAL Trial

TEL AVIV, Israel, Dec. 07, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that the Company's Chairman of the Board, Dr. Bennett Shapiro, the CEO, Prof. Dror Harats and additional Company board members and senior management, made open-market purchases of approximately 200K shares of VBLT, between November 24 and December 3, 2020.

VBL Therapeutics Announces Insider Buying

Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q3 2020 Results - Earnings Call Transcript

Shares of Vascular Biogenics (NASDAQ:VBLT) moved higher by 0.8% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 14.29% year over year to ($0.12), which beat the estimate of ($0.13).

Vascular Biogenics: Q3 Earnings Insights

- Continued progress in OVAL Phase 3 potential-registration study in patients with platinum-resistant ovarian cancer; high response rates (RR) of over 50% in the total evaluable patient population with approximately 200 patients enrolled to date

VBL Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

TEL AVIV, Israel, Nov. 05, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces that Prof. Dror Harats, M.D., Chief Executive Officer, will provide a corporate overview, in a format of a fireside chat with analyst Swayampakula Ramakanth, Ph.D. (RK), at the H.C. Wainwright 6th Annual Israel Conference to be held virtually on November 12th, 2020.

VBL Therapeutics to Present at the H.C. Wainwright 6th Annual Israel Conference

TEL AVIV, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Monday, November 16, 2020 at 8:30am Eastern Time to report third quarter ended September 30, 2020 financial results and to provide a corporate update.

VBL Therapeutics to Report Third Quarter 2020 Financial Results on November 16

TEL AVIV, Israel, Oct. 13, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that it has appointed Marc Kozin as Vice Chairman of the Board. Mr. Kozin will transition to becoming Chairman during 2021, at which time Bennett Shapiro, M.D., the current Chairman of the Board, will step down as Chairman. Dr. Shapiro will remain on the Board of Directors.

VBL Therapeutics Announces Appointment of Marc Kozin as Vice Chairman of Board of Directors

TEL AVIV, Israel, Oct. 12, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that the European Patent Office (EPO) has granted Patent #3328408, which covers VBL’s proprietary investigational anti-MOSPD2 monoclonal antibodies to treat inflammatory conditions. VBL is currently advancing its lead anti-MOSPD2 candidate through IND-enabling studies.

Newly Granted European Patent Protects VBL Therapeutics' Anti-MOSPD2 Antibodies for Inflammation Until at least July 2036

TEL AVIV, Israel, Sept.  29, 2020  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced Prof. Dror Harats, M.D., Chief Executive Officer, will provide a corporate overview, in a format of a fireside chat with analyst Geulah Livshits, PhD, at the Chardan 4th Annual Genetic Medicines Conference, to be held virtually October 5-6 2020.

VBL Therapeutics to Present at the Chardan 4th Annual Genetic Medicines Conference

TEL AVIV, Israel, Sept.  21, 2020  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces that Prof. Dror Harats, M.D., Chief Executive Officer, will provide a corporate overview, at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held virtually September 21-23, 2020.

VBL Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

TEL AVIV, Israel, Sept.  15, 2020  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) will present today a corporate overview, including an update on the OVAL pivotal study, at the H. C. Wainwright 22nd Annual Global Investment Conference being held virtually on September 14-16, 2020.  

VBL Therapeutics to Provide an Update on the OVAL Study Today at the H. C. Wainwright 22nd Annual Global Investment Conference

TEL AVIV, Israel, Sept.  11, 2020  (GLOBE NEWSWIRE) --  VBL Therapeutics  (Nasdaq:  VBLT ), today presents for the first time new data demonstrating ex-vivo activity of its proprietary investigational anti-MOSPD2 mAbs in patients with relapsing-remitting and progressive multiple sclerosis (MS). VBL's study is being presented at the  MS Virtual 2020, the virtual 8th Joint ACTRIMS-ECTRIMS Meeting .

VBL Presents Human Proof-of-Concept Data That Show the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Multiple Sclerosis at the MS Virtual 2020 Meeting

TEL AVIV, Israel, Sept.  10, 2020  (GLOBE NEWSWIRE) --  VBL Therapeutics (Nasdaq: VBLT) announced today that the first two patients have been enrolled in the Phase 2 clinical trial of VB-111 in combination with nivolumab (Opdivo®), an immune checkpoint inhibitor, for the treatment of metastatic colorectal cancer. The study is being conducted under a Cooperative Research and Development Agreement (CRADA) between the National Cancer Institute (NCI) and VBL.

VBL Therapeutics Announces Enrollment of the First Patients in the Phase 2 Clinical Trial of VB-111 in Metastatic Colorectal Cancer

TEL AVIV, Israel, Sept.  08, 2020  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today the successful completion of a Type B pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding the Company's development plan for VB-601. VB-601 is the Company’s lead anti-MOSPD2 antibody for immune-inflammatory indications, for which a briefing package for the pre-IND meeting was submitted in June. Based on the FDA's feedback, VBL plans to advance its IND-enabling activities for VB-601 as planned.

VBL Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Clinical Development of VB-601

Vascular Biogenics Ltd (VBLT) CEO Dror Harats on Q2 2020 Results - Earnings Call Transcript

Shares of Vascular Biogenics (NASDAQ:VBLT) decreased 9% in pre-market trading after the company reported Q2 results.

Vascular Biogenics: Q2 Earnings Insights

TEL AVIV, Israel, Aug.  12, 2020  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that the independent Data Safety Monitoring Committee (DSMC) has completed its second, pre-planned interim analysis in the ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111) in patients with platinum-resistant ovarian cancer, and unanimously recommended that the study continue as planned. 

VBL Therapeutics Announces Second Successful Pre-planned Interim Analysis with a Positive Data Safety Monitoring Committee Review Looking at OS - the Primary Endpoint of the OVAL Phase 3 Potential Registration Study of VB-111 in Ovarian Cancer

Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Vascular Biogenics (VBLT) Q2 Earnings Expected to Decline

TEL AVIV, Israel, Aug.  03, 2020  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Thursday, August 13, 2020 at 8:30am Eastern Time to report second quarter ended June 30, 2020 financial results and to provide a corporate update.

VBL Therapeutics to Report Second Quarter 2020 Financial Results on August 13

The company's bi-specific antibody candidates significantly prolonged survival in models of metastatic human cervical and breast cancer The company's bi-specific antibody candidates significantly prolonged survival in models of metastatic human cervical and breast cancer

VBL Therapeutics Presents MOSPD2 Bi-Specific Antibody Activity and Potential Survival Benefit for Solid Tumors in Late Breaking Research Session of the AACR Virtual Annual Meeting

TEL AVIV, Israel, June  01, 2020  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced the presentation of the positive outcome of pre-planned interim analysis results from the OVAL Phase 3 pivotal clinical trial in platinum-resistant ovarian cancer at the  American Society of Clinical Oncology (ASCO) 2020  virtual annual meeting.

VBL Presents Positive Interim Data from the OVAL Phase 3 Pivotal Study in Ovarian Cancer at the ASCO20 Annual Meeting, Showing 58% or Higher Objective Response Rate

Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q1 2020 Results - Earnings Call Transcript

Shares of Vascular Biogenics (NASDAQ:VBLT) were flat in pre-market trading after the company reported Q1 results.

News for Vascular Biogenics Stock (VBLT)